Paolo F Caimi1, Kirit M Ardeshna2, Erin Reid3, Weiyun Ai4, Matthew Lunning5, Jasmine Zain6, Melhem Solh7, Brad S Kahl8, Mehdi Hamadani9. 1. Cleveland Clinic/Case Comprehensive Cancer Center, Cleveland, OH. Electronic address: caimip@ccf.org. 2. Department of Hematology, University College London Hospitals (UCLH) NHS Foundation Trust, London, UK. 3. Division of Hematology and Oncology, Department of Medicine, University of California, San Diego, CA. 4. Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, CA. 5. Division of Oncology and Hematology, Department of Medicine, University of Nebraska Medical Center, Omaha, NE. 6. Department of Hematology & Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, CA. 7. Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA. 8. Department of Medicine, Oncology Division, Washington University, St. Louis, MO. 9. BMT & Cellular Therapy Program, Medical College of Wisconsin, Milwaukee, WI.
Abstract
INTRODUCTION: Chimeric antigen receptor T (CAR-T) cells targeting CD19 result in durable responses in approximately 40% of DLBCL patients. Loncastuximab tesirine, an antibody drug conjugate targeting CD19 with a pyrrolobenzodiazepine payload, has activity against DLBCL. PATIENTS AND METHODS: We evaluated the outcomes of 13 DLBCL patients relapsed after CAR-T cells treated with loncastuximab in the LOTIS-2 trial. RESULTS: Six patients (46%) had responses to loncastuximab (CR, n = 2). Median OS, PFS and duration of response after loncastuximab were 8.2, 1.4 and 8 months, respectively. CONCLUSION: Loncastuximab can achieve responses in patients progressing after CAR-T cells. Sequencing CD19-targeting therapies is possible in cases without CD19 loss.
INTRODUCTION: Chimeric antigen receptor T (CAR-T) cells targeting CD19 result in durable responses in approximately 40% of DLBCL patients. Loncastuximab tesirine, an antibody drug conjugate targeting CD19 with a pyrrolobenzodiazepine payload, has activity against DLBCL. PATIENTS AND METHODS: We evaluated the outcomes of 13 DLBCL patients relapsed after CAR-T cells treated with loncastuximab in the LOTIS-2 trial. RESULTS: Six patients (46%) had responses to loncastuximab (CR, n = 2). Median OS, PFS and duration of response after loncastuximab were 8.2, 1.4 and 8 months, respectively. CONCLUSION: Loncastuximab can achieve responses in patients progressing after CAR-T cells. Sequencing CD19-targeting therapies is possible in cases without CD19 loss.
Authors: Miguel-Angel Perales; Larry D Anderson; Tania Jain; Saad S Kenderian; Olalekan O Oluwole; Gunjan L Shah; Jakub Svoboda; Mehdi Hamadani Journal: Transplant Cell Ther Date: 2022-06-26
Authors: Ana Carolina Caballero; Laura Escribà-Garcia; Carmen Alvarez-Fernández; Javier Briones Journal: Front Immunol Date: 2022-07-06 Impact factor: 8.786